Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | OTC | P00480 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19135682 | 0.92 | GLP1R (0.51) | GLP1RNOD1OTCTDP1DDAH1 | |
| SCHEMBL20706160 | 0.89 | GLP1R (0.49) | GLP1RNOD1OTCTDP1DDAH1 | |
| SCHEMBL22030229 | 0.87 | GLP1R (0.57) | GLP1RNOD1 | |
| SCHEMBL22026239 | 0.87 | GLP1R (0.57) | GLP1RNOD1 | |
| SCHEMBL19152795 | 0.85 | GLP1R (0.46) | GLP1RNOD1OTCTDP1 | |
| SCHEMBL20900405 | 0.85 | GLP1R (0.57) | GLP1R | |
| SCHEMBL22174980 | 0.84 | GLP1R (0.42) | GLP1RNOD1OTCMEN1KMT2A | |
| SCHEMBL19135688 | 0.84 | GLP1R (0.59) | GLP1R | |
| SCHEMBL24483719 | 0.84 | GLP1R (0.59) | GLP1R | |
| SCHEMBL21725212 | 0.84 | GLP1R (0.55) | GLP1RNOD1OTC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009989-A1 | BIFUNCTIONAL COMPOUNDS COMPRISING INSULIN PEPTIDES AND EGF(A) PEPTIDES | NOVO NORDISK A/S (DK) | 2022-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009989-A1 | BIFUNCTIONAL COMPOUNDS COMPRISING INSULIN PEPTIDES AND EGF(A) PEPTIDES | IAPP, IGFBP1, IGFBP2 | GLP1R 16/4885NOD1 2091/4885LTA4H 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.